Cegedim (ALCGM) AI Stock Analysis

• Market Cap: €182.40M
• Dividend Yield: N/A
• Average Volume (3M): 9.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 3.79%
• EPS Growth: -797.10%
• Country: FR
• Employees: 6,700
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.10
• Shares Outstanding: 14,097,155
• 10 Day Avg. Volume: 11,588
• 30 Day Avg. Volume: 9,646
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €14.00
• Price Target Upside: 29.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: €13.00 ▲(20.37% Upside)

Cegedim's overall stock score is primarily influenced by its solid revenue growth and strong technical momentum. However, challenges with profitability, financial stability, and valuation concerns due to a negative P/E ratio and lack of dividend yield weigh down the score. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for Cegedim's healthcare solutions, supporting long-term business expansion and market presence.

Cash Flow Generation

Strong operating cash flow generation reflects the company's ability to effectively convert sales into cash, ensuring liquidity and operational flexibility.

Gross Profit Margin

A strong gross profit margin suggests effective cost management at the production level, which can support profitability as the company scales.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, marked by negative net income, indicate struggles in cost management and achieving operational efficiencies.

Financial Stability Risks

Increased debt levels and reduced equity can strain financial stability, limiting the company's ability to invest in growth and weather economic downturns.

Free Cash Flow Volatility

Volatile free cash flow can hinder long-term investment and dividend capabilities, impacting shareholder value and financial planning.

Cegedim Business Overview & Revenue Model

Company Description

Cegedim (ALCGM) is a global technology and services company specializing in the healthcare and insurance sectors. Founded in 1969, Cegedim offers a wide range of solutions including software development, data management, and consulting services tailored to healthcare professionals, payers, and pharmaceutical companies. The company's core products include healthcare CRM solutions, electronic health record systems, and data analytics services that enhance operational efficiency and improve patient care.

How the Company Makes Money

Cegedim generates revenue through multiple streams, primarily by providing software solutions and data services to healthcare organizations and pharmaceutical companies. Key revenue models include subscription fees for software licenses, transaction fees for data services, and consulting fees for strategic advisory services. Cegedim also benefits from partnerships with major healthcare stakeholders, including pharmaceutical firms and insurance companies, which enhance its market reach and credibility. Additionally, the company may earn revenue through research and development contracts, leveraging its expertise in healthcare analytics and technology.

Cegedim Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cegedim Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCGM, the sentiment is Positive. The current price of 10.8 is below the 20-day moving average (MA) of 12.62, below the 50-day MA of 11.75, and below the 200-day MA of 11.37, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 72.85 is Negative, neither overbought nor oversold. The STOCH value of 78.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALCGM.

Cegedim Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQS	74 Outperform	€550.50M	15.17	16.40%	2.89%	4.45%	-14.08%
ALKEY	62 Neutral	€124.50M	9.16	―	―	-4.16%	―
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ALCGM	60 Neutral	€182.40M	―	-5.21%	―	3.79%	-797.10%
AL2SI	52 Neutral	€253.74M	119.04	―	―	―	―
CLA	45 Neutral	€93.88M	-27.65	―	―	-0.95%	49.19%